Eastridge B J, Lefor A T
Department of Surgery, University of Maryland, Baltimore.
J Clin Oncol. 1995 Jan;13(1):233-8. doi: 10.1200/JCO.1995.13.1.233.
We undertook this study to review our experience with indwelling vascular access devices in cancer patients to identify factors associated with complications.
A total of 322 indwelling devices were placed in 274 cancer patients by a single surgeon. Devices were placed via percutaneous insertion in 72% (231 of 322) and via venous cutdown in 28% (91 of 322). We placed external catheters in 209 of 322 patients (65%) and subcutaneous infusion ports in 113 of 322 (35%).
Pneumothorax occurred in four of 231 (1.7%) of the percutaneously placed devices. Postoperative complications included sepsis and thrombosis, which necessitated premature removal of the devices. Device related sepsis occurred in 28 of 209 patients (13%) with catheters and six of 113 patients (5%) with subcutaneous ports. Thrombosis occurred in 21 of 209 patients (10%) with catheters and seven of 113 (6%) with subcutaneous ports. In 15 of 19 devices removed for thrombosis, the tip was above the T3 level. Seventeen devices were placed in the saphenous vein, with a complication rate similar to that observed in upper-body devices.
We found a significantly (P < .05, chi 2 analysis) increased incidence of thrombotic complications in patients with triple-lumen catheters (10 of 48) compared with double-lumen catheters (11 of 160), as well as a significantly (P < .05) decreased mean time until catheter failure (40 v 146 days). We also observed a significant increase in the rate of thrombosis in patients with a catheter tip above the T3 level. We therefore recommend the use of fluoroscopy at the time of placement to assure adequate catheter length and tip position and the use of triple-lumen catheters only when necessary for concurrent drug administration.
我们开展这项研究以回顾我们在癌症患者中使用留置血管通路装置的经验,从而确定与并发症相关的因素。
由一名外科医生为274例癌症患者共置入322个留置装置。72%(322个中的231个)通过经皮穿刺置入装置,28%(322个中的91个)通过静脉切开置入。322例患者中有209例(65%)置入了外置导管,322例中有113例(35%)置入了皮下输注端口。
231个经皮置入的装置中有4个(1.7%)发生气胸。术后并发症包括败血症和血栓形成,这使得装置不得不提前拔除。209例使用导管的患者中有28例(13%)发生与装置相关的败血症,113例使用皮下端口的患者中有6例(5%)发生。209例使用导管的患者中有21例(10%)发生血栓形成,113例使用皮下端口的患者中有7例(6%)发生。在因血栓形成而拔除的19个装置中,有15个的尖端位于T3水平以上。17个装置置入了大隐静脉,其并发症发生率与上身装置相似。
我们发现,与双腔导管(160个中的11个)相比,三腔导管患者(48个中的10个)血栓形成并发症的发生率显著增加(P <.05,卡方分析),并且导管失效的平均时间显著缩短(40天对146天,P <.05)。我们还观察到导管尖端位于T3水平以上的患者血栓形成率显著增加。因此,我们建议在置入时使用荧光透视以确保导管长度和尖端位置合适,并且仅在同时给药必要时才使用三腔导管。